8 not yet recruiting, 4 recruiting, 1 active not recruiting, 1 completed. 9 Phase 2, 5 Phase 3, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Not yet recruiting 5, Active not recruiting 1, Completed 1, Recruiting 1, Withdrawn 1 |
| Phase 3 | 5 | Not yet recruiting 3, Recruiting 2 |
| Phase 1 | 3 | Completed 1, Recruiting 1, Withdrawn 1 |
Follow Gemcitabine (GEM): new trials by email Literature Review of Gemcitabine (GEM) trials Research Report on Gemcitabine (GEM)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Toripalimab ± Sequential Intravesical Gemcitabine-Mitomycin C for BCG-Unresponsive/-Intolerant High-Risk NMIBC: Open-Label Randomized Phase 2 Study Toripalimab, Gemcitabine (GEM), Mitomycin C (MMC) - Urinary Bladder Neoplasms, Carcinoma, Transitional Cell | Phase 2 | Not yet recruiting | First Affiliated Hospital of Wenzhou Medical University | 106 | 2026-12-01 | 2026-09-08 |
| Toripalimab Combined With Intravesical Gemcitabine as Adjuvant Therapy for High-Risk Non-Muscle-Invasive Bladder Cancer After TURBT Toripalimab (JS001 ), Gemcitabine (GEM) - Non Muscle Invasive Bladder Cancer | Phase 2 | Not yet recruiting | Tianjin First Central Hospital | 54 | 2026-10-01 | 2026-09-08 |
| JSKN033 Versus Investigator's Choice of Chemotherapy in Recurrent or Metastatic Cervical Cancer JSKN033, Docetaxel, Topotecan - Recurrent or Metastatic Cervical Cancer | Phase 3 | Not yet recruiting | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | 368 | 2026-09-01 | 2026-09-01 |
| GELAD-Based Response-Adapted Treatment for Early-Stage Extranodal NK/T-Cell Lymphoma Gemcitabine (GEM), Etoposide Injection, Dexamethasone - Natural Killer/T-cell Lymphoma | Phase 2 | Not yet recruiting | Fudan University | 620 | 2026-09-01 | 2026-08-17 |
| Prospective Observational Study of Outcomes After Gemcitabine, Docetaxel, Melphalan, and Carboplatin With Autologous Stem Cell Transplantation in Pediatric Relapsed/Refractory Germ Cell Tumors Gemcitabine (GEM), Docetaxel, Melphalan - Prospective Observational Study, Gemcitabine | Recruiting | M.D. Anderson Cancer Center | 30 | 2026-06-05 | 2026-06-23 | |
| Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 ) Zoldonrasib, Placebo, Oxaliplatin - Pancreatic Cancer, Pancreatic Cancer Metastatic | Phase 3 | Recruiting | Revolution Medicines, Inc. | 670 | 2026-05-22 | 2026-10-13 |
| Selinexor Combined With Reduced-Dose Radiotherapy For Early-Stage Extranodal NK/T-Cell Lymphoma Pegaspargase (PEG) Asparaginase, Gemcitabine (GEM), Oxaliplatin - Extranodal NK/T-cell Lymphoma | Phase 2 | Not yet recruiting | Beijing Tongren Hospital | 34 | 2026-05-15 | 2026-04-28 |
| Becotatug Vedotin Plus Sintilimab in Locoregionally Advanced NPC Becotatug Vedotin, Sintilimab, Cisplatin - Nasopharyngeal Carcinoma (NPC) | Phase 3 | Recruiting | First Affiliated Hospital of Guangxi Medical University | 266 | 2026-03-05 | 2026-03-16 |
| Anlotinib Plus Immunotherapy and Chemoradiotherapy for High-Risk Nasopharyngeal Carcinoma Anlotinib Hydrochloride Capsules, Gemcitabine (GEM), Cisplatin - Nasopharyngeal Cancinoma (NPC), Nasopharyngeal Cancer | Phase 3 | Not yet recruiting | Sun Yat-sen University | 412 | 2026-03-01 | 2026-02-03 |
| A Study of FG-M108+Chemotherapy vs Placebo+Chemotherapy in Claudin18.2-positive Pancreatic Cancer FG-M108, nab paclitaxel, Gemcitabine (GEM) - Pancreatic Cancer | Phase 3 | Not yet recruiting | FutureGen Biopharmaceutical (Beijing) Co., Ltd | 524 | 2026-02-28 | 2026-02-04 |
| A Study of MR001 Combined With Chemotherapy in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) After First-line Therapy MR001, Irinotecan Liposome Injection combined with 5-FU/LV, Nab-paclitaxel - Pancreatic Ductal Adenocarcinoma (PDAC) | Phase 1 / Phase 2 | Recruiting | Shenzhen Majory Biotechnology Co., Ltd. | 45 | 2025-12-24 | 2026-05-26 |
| Perioperative Chemotherapy and Immunotherapy for Locally Recurrent Nasopharyngeal Carcinoma Gemcitabine (GEM), Cisplatin, PEMBROLIZUMAB (alone or when added to a regimen above) - Nasopharyngeal Cancer Recurrent, Nasopharyngeal Cancinoma (NPC) | Phase 2 | Not yet recruiting | The University of Hong Kong | 53 | 2025-11-01 | 2025-09-04 |
| Neoadjuvant Chemotherapy Plus Toripalimab in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma Toripalimab, Gemcitabine (GEM), Cisplatin - Nasopharyngeal Carcinoma | Phase 2 | Active not recruiting | Zhejiang Cancer Hospital | 89 | 2023-04-21 | 2026-07-10 |
| HCW9218 for Advanced Pancreatic Cancer HCW9218, Gemcitabine (GEM), Nab-paclitaxel - Advanced Pancreatic Carcinoma | Phase 1 / Phase 2 | Completed | ImmunityBio, Inc. | 21 | 2022-10-17 | 2026-04-15 |
| Study of Sotorasib Combined With Chemotherapy for Second Line Treatment of Pancreas Cancer Sotorasib, Liposomal Irinotecan (nal-IRI), 5 Fluorouracil (5FU) - Pancreatic Cancer, Unresectable Pancreatic Cancer | Phase 1 / Phase 2 | Withdrawn | Devalingam Mahalingam | 2022-09-13 | 2023-05-11 |
Nasopharyngeal Carcinoma (3) · Pancreatic Neoplasms (3) · Lymphoma, Extranodal NK-T-Cell (2) · Non-Muscle Invasive Bladder Neoplasms (2) · Urinary Bladder Neoplasms (2) · Carcinoma in Situ (1) · Carcinoma, Transitional Cell (1) · Nasopharyngeal Neoplasms (1) · Recurrence (1) · Uterine Cervical Neoplasms (1)
Beijing Tongren Hospital (1) · Devalingam Mahalingam (1) · First Affiliated Hospital of Guangxi Medical University (1) · First Affiliated Hospital of Wenzhou Medical University (1) · Fudan University (1) · FutureGen Biopharmaceutical (Beijing) Co., Ltd (1) · ImmunityBio, Inc. (1) · Jiangsu Alphamab Biopharmaceuticals Co., Ltd (1) · M.D. Anderson Cancer Center (1) · Revolution Medicines, Inc. (1) · Shenzhen Majory Biotechnology Co., Ltd. (1) · Sun Yat-sen University (1) · The University of Hong Kong (1) · Tianjin First Central Hospital (1) · Zhejiang Cancer Hospital (1)
China (8) · United States (4) · Hong Kong (1) · United Kingdom (1)
Chuanxu Liu, MD (1) · Devalingam Mahalingam, MD (1) · Irtiza N Sheikh, MD (1) · Jun Ma, M.D. (1) · Liang Wang (1) · Paula Bradshaw, MSN, MBA, RN (1) · Rong Tao, MD (1) · Victor Ho-Fun Lee, MD (1) · Xuejun Ma, MD (1) · Zhaoyu Jin, Ph.D (1)
PMID 19171491, PMID 23510863, PMID 34051177, PMID 34702811, PMID 34806163, PMID 37596191, PMID 38265030, PMID 38740030